A5008991955- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- Hemoglobinopathies and Related Disorders
- Nutrition, Genetics, and Disease
- Erythrocyte Function and Pathophysiology
- Cancer Genomics and Diagnostics
- Neonatal Health and Biochemistry
- Cancer Immunotherapy and Biomarkers
- Iron Metabolism and Disorders
- Blood groups and transfusion
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Cancer Risks and Factors
- Gene expression and cancer classification
- Blood Coagulation and Thrombosis Mechanisms
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Blood disorders and treatments
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
Universitat de Barcelona
2022-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2019-2025
Hospital Clínic de Barcelona
2020-2025
Departament de Salut
2023-2024
Target (United States)
2022-2024
Fundació Clínic per a la Recerca Biomèdica
2023-2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2023-2024
Breast Cancer Research Foundation
2022-2024
Biomedical Research Institute
2022-2024
University of Naples Federico II
1962-2023
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical molecular features HER2-low BC yet to be elucidated. Here, we collected retrospective clinicopathological PAM50 data from 3,689 patients disease made following observations. First, proportion was higher HR-positive (65.4%) than triple-negative (TNBC, 36.6%). Second, within disease, luminal-related...
The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this detects most mutations in BC. This information critical as clinicians using other genomic assays indicate alpelisib.Data from 6338 BC was explored across 10 publicly available studies. primary objective evaluate proportion distribution of...
Both clinical and genomic data independently predict survival treatment response in early-stage HER2-positive breast cancer. Here we present the development validation of a new HER2DX risk score, pathological complete (pCR) both based on 27-gene expression plus feature-based classifier.HER2DX is supervised learning algorithm incorporating tumour size, nodal staging, 4 gene signatures tracking immune infiltration, cell proliferation, luminal differentiation, HER2 amplicon, into single score....
Summary. In 1997, the Italian Ministry of Health created a special programme for controlled distribution deferiprone to collect data and evaluate its safety effectiveness in long‐term use. Five hundred thirty‐two thalassaemia patients from 86 treatment centres were enrolled this programme. One eighty‐seven (32%) experienced total 269 events that led temporary interruption or, some cases, discontinuation treatment. The incidence agranulocytosis milder neutropenias 0·4/100 2·1/100...
Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a standpoint, immune infiltration plays crucial role in TNBC prognosis. Currently, there is lack of genomic tools aiding treatment decisions for TNBC. This study aims to assess the effectiveness B-cell/immunoglobulin signature (IGG) alone, or combination with tumor burden, predicting prognosis response patients
Abstract Background Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)‐low‐expressing BC has recently emerged as a novel therapeutic target not been characterized this rare patient subset. Methods Women newly diagnosed early‐stage HER2‐negative (HER2‐0 and HER2‐low) PVs from 78 health care centers worldwide were retrospectively...
Abstract Background The optimal treatment approach for hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-negative MBC) with aggressive characteristics remains controversial, lack of randomized trials comparing cyclin-dependent kinase (CDK)4/6-inhibitors (CDK4/6i) + endocrine therapy (ET) chemotherapy ET. Materials and methods We conducted an open-label phase II trial (NCT03227328) to investigate whether ET is superior CDK4/6i HR+/HER2-negative MBC features. PAM50...
The characterization and comparison of gene expression intrinsic subtype (IS) changes induced by neoadjuvant chemotherapy (NACT) endocrine therapy in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-low versus HR+/HER2-0 breast cancer (BC) has not been conducted so far. Most evidence on the association HER2 status with pathologic responses prognosis HR+/HER2-negative BC is controversial restricted to NACT-treated disease. Similarly, a temporal heterogeneity...
Abstract Objectives: Breast cancer is one of the most common malignancies in women. Hormonal treatment and chemotherapy induce a transient or permanent menopause status. Vulvovaginal atrophy (VVA) frequent debilitating symptom that best treated with local systemic estrogen formulations. Because estrogens drive growth majority breast cancers, effective VVA therapies are precluded. The aim this study was to evaluate effects fractional microablative CO 2 laser on sexual function relieving...
Abstract Objective: Vulvovaginal atrophy (VVA) is a condition frequently observed in menopause. Its symptoms can significantly affect the quality of life patients. Since VVA related to estrogen deficiency, chemotherapy and hormone therapy for breast cancer (BC) might cause by inducing Given lack effective treatment BC survivors, we retrospectively evaluated efficacy tolerability fractional microablative CO 2 laser these Methods: We treated 82 survivors with three cycles after failure topical...
Abstract Purpose Obesity and insulin resistance have been associated with poor prognosis in breast cancer (BC). The present prospective study aimed to investigate the impact of metabolic syndrome (MetS) its components on early BC (eBC) patients’ outcome. Methods MetS was defined by presence 3 5 following components: waist circumference > 88 cm, blood pressure ≥ 130/≥ 85 mmHg, serum levels triglycerides 150 mg/dL, high density lipoprotein < 50 mg/dL fasting glucose 110 mg/dL. Seven...
Abstract Objective: The objective of this study was to evaluate the efficacy rescue fractional microablative CO 2 laser treatment in women with severe symptoms and sexual dysfunction related lichen sclerosus not responsive long-term ultra-potent topical corticosteroid treatment. Methods: Consecutive eligible referred our unit who received after failure were enrolled study. diagnosis confirmed by histological assessment all cases. Patients underwent two cycles every 30 40 days. severity...
In advanced breast cancer, biomarker identification and patient selection using a metastatic tumor biopsy is becoming more necessary. However, the biology of metastasis according to organ site largely unknown. Here, we evaluated expression 771 genes in 184 samples across 11 organs, including liver, lung, brain, bone, made following observations. First, all PAM50 molecular intrinsic subtypes were represented organs within immunohistochemistry-based groups. Second, HER2-low disease was...